The win is Abbott’s third in a row in federal court in Chicago where hundreds of cases over specialized formulas for preterm ...
Abbott Laboratories (ABT) stock has drifted slightly lower this month, with shares showing a 7% drop over the past month.
The fate of hundreds of pending cases against Abbott and Mead Johnson hang in the balance with the latest dismissal.
Investor's Business Daily on MSN
S&P 500 Health Giant Abbott Labs Skids On Mixed Report. But One Segment Shined.
Abbott stock skidded Wednesday after the S&P 500 health giant missed the Street's third-quarter sales forecast, but met ...
Abbott Laboratories (NYSE:ABT) traded ~3% lower in the premarket on Wednesday after the MedTech giant’s Q3 2025 results ...
Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the ...
Walmart will become the first U.S. retailer to sell Abbott Laboratories' over-the-counter continuous glucose monitor Lingo in ...
Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that ...
Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical ...
According to a filing with the Securities and Exchange Commission dated October 14, 2025, CCLA Investment Management ...
The stock's fall snapped a two-day winning streak.
Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback